Advanced Cancer
Conditions
Brief summary
This is a Phase 1 study during which patients with advanced solid tumors will receive a new formulation of investigational study drug ARRY-334543. Patients will receive increasing doses of study drug in order to achieve the highest dose possible that will not cause unacceptable side effects. The patients will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. In addition, the effect of food on the new formulation will be evaluated. Approximately 24 patients from Canada will be enrolled in this study (Active, not recruiting).
Interventions
single dose and multiple dose, escalating
Sponsors
Array Biopharma, now a wholly owned subsidiary of Pfizer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Histological or cytological evidence of malignancy. * Patients with advanced solid tumors who are no longer candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy. * Cardiac ejection fraction ≥ 50% by echocardiogram (ECHO) or multiple gated acquisition (MUGA). * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2. * Additional criteria exist. Key
Exclusion criteria
* Uncontrolled brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days). * Use of an investigational medication or device within 30 days prior to first dose of study drug. * Major surgery within 30 days prior to first dose of study drug. * Radiotherapy or chemotherapy within 28 days prior to first dose of study drug (not including palliative radiotherapy at focal sites). * Active, uncontrolled infection requiring systemic antibiotic therapy or other serious underlying medical condition which would impair the ability of the patient to receive protocol treatment. * Pregnancy or lactation. * Known positive serology for the human immunodeficiency virus (HIV), 'active' hepatitis B and/or hepatitis C. * Additional criteria exist.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Characterize the safety profile of the new formulation of study drug in terms of adverse events, clinical laboratory tests and electrocardiograms. | Duration of study |
| Establish the maximum tolerated dose (MTD) of the new formulation of study drug. | Duration of study |
| Characterize the pharmacokinetics (PK) of the new formulation of study drug (in terms of plasma concentrations) when administered in a fed versus fasted state. | Day 1 and Day 8 |
| Assess the exposure of the new formulation of study drug in terms of plasma concentrations. | Duration of study |
Secondary
| Measure | Time frame |
|---|---|
| Assess the efficacy of the new formulation of study drug in terms of tumor dimension assessment. | Duration of study |
Countries
Canada
Outcome results
None listed